Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
F&O
Mutual Funds
Invest in Mutual Funds
Invest in direct mutual funds at zero charges via lump sump investments or SIPs
ITI Pharma and Healthcare Fund Direct Growth
+20.97%
3Y annualised
+0.25% 1D
NAV: 28 Aug '26
₹20.11
Min. for SIP
₹500
Fund size (AUM)
₹262.84 Cr
Expense ratio
0.92%
Rating
2
Return calculator
Monthly investment
₹5,000
| Over the past | Total investment | Would've become | Historic returns | Returns |
|---|---|---|---|---|
| 3 months | ₹15,000 | ₹15,835 | +5.57% | |
| 6 months | ₹30,000 | ₹32,208 | +7.36% | |
| 1 year | ₹60,000 | ₹63,713 | +6.19% | |
| 3 years | ₹1,80,000 | ₹2,19,201 | +21.78% |
Holdings (39)
| Name | Sector | Instruments | Assets |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 13.26% |
| Divi's Laboratories Ltd | Healthcare | Equity | 7.97% |
| Apollo Hospitals Enterprise Ltd | Healthcare | Equity | 6.05% |
| Max Healthcare Institute Ltd | Healthcare | Equity | 5.05% |
| Torrent Pharmaceuticals Ltd | Healthcare | Equity | 4.84% |
| Cipla Ltd | Healthcare | Equity | 4.43% |
| Dr. Reddy's Laboratories Ltd | Healthcare | Equity | 4.41% |
| Laurus Labs Ltd | Healthcare | Equity | 4.21% |
| Aurobindo Pharma Ltd | Healthcare | Equity | 3.84% |
| Mankind Pharma Ltd. | Healthcare | Equity | 3.39% |
| Suven Pharmaceuticals Ltd | Healthcare | Equity | 3.04% |
| Neuland Laboratories Ltd | Healthcare | Equity | 3.03% |
| Global Health Ltd | Healthcare | Equity | 2.98% |
| Alkem Laboratories Ltd | Healthcare | Equity | 2.92% |
| Lupin Ltd | Healthcare | Equity | 2.82% |
| Fortis Healthcare Ltd | Healthcare | Equity | 2.79% |
| Net Receivables | Unspecified | Net Receivables | 2.11% |
| Abbott India Ltd | Healthcare | Equity | 1.90% |
| Poly Medicure Ltd | Healthcare | Equity | 1.52% |
| Ipca Laboratories Ltd | Healthcare | Equity | 1.50% |
| Aster DM Healthcare Ltd | Healthcare | Equity | 1.35% |
| Sai Life Sciences Ltd. | Healthcare | Equity | 1.32% |
| Piramal Pharma Ltd | Healthcare | Equity | 1.27% |
| Shaily Engineering Plastics Ltd | Materials | Equity | 1.23% |
| Healthcare Global Enterprises Ltd | Healthcare | Equity | 1.21% |
| Shilpa Medicare Ltd | Healthcare | Equity | 1.15% |
| Linde India Ltd | Materials | Equity | 1.10% |
| Glenmark Pharmaceuticals Ltd | Healthcare | Equity | 1.09% |
| Rainbow Childrens Medicare Ltd | Healthcare | Equity | 1.05% |
| Biocon Ltd | Healthcare | Equity | 0.95% |
| Glaxosmithkline Pharmaceuticals Ltd | Healthcare | Equity | 0.93% |
| Supriya Lifescience Ltd | Healthcare | Equity | 0.92% |
| Medplus Health Services Ltd | Healthcare | Equity | 0.88% |
| Zydus Lifesciences Ltd | Healthcare | Equity | 0.72% |
| Venus Pipes & Tubes Ltd | Industrials | Equity | 0.69% |
| Syngene International Ltd | Healthcare | Equity | 0.61% |
| Caplin Point Laboratories Ltd | Healthcare | Equity | 0.54% |
| Bharat Dynamics Ltd | Industrials | Equity | 0.47% |
| Yes Bank Ltd | Financial | Equity | 0.46% |
See All
Minimum investments
Min. for 1st investment
₹5,000
Min. for 2nd investment
₹1,000
Min. for SIP
₹500
Returns and rankings
Annualised returns
Absolute returns
| Name | 6M | 1Y | 3Y | All |
|---|---|---|---|---|
| Fund returns | +19.2% | +16.4% | +21.0% | +15.6% |
| Category average (Equity Sectoral) | +0.2% | -2.1% | +22.1% | -- |
| Rank (Equity Sectoral) | -- | 16 | 8 | -- |
Exit load, stamp duty and tax
Exit load
Exit load of 0.50%, if redeemed within 3 months.
Stamp duty on investment: 0.005% (from July 1st, 2020)
from July 1st 2020
Tax implication
If you redeem within one year, returns are taxed at 20%. If you redeem after one year, returns exceeding Rs 1.25 lakh in a financial year are taxed at 12.5%.
Check past data
Fund management
ASAnimesh SinghMay 2026 - PresentView details
AS
Animesh Singh
May 2026 - Present
View details
NDNilay DalalMay 2026 - PresentView details
ND
Nilay Dalal
May 2026 - Present
View details
About ITI Pharma and Healthcare Fund Direct Growth
ITI Pharma and Healthcare Fund Direct Growth is a Equity Mutual Fund Scheme launched by ITI Mutual Fund. This scheme was made available to investors on 14 May 2018. Animesh Singh is the Current Fund Manager of ITI Pharma and Healthcare Fund Direct Growth fund. The fund currently has an Asset Under Management(AUM) of ₹12,250 Cr and the Latest NAV as of 28 Aug 2026 is ₹20.11.
The ITI Pharma and Healthcare Fund Direct Growth is rated Very High risk. Minimum SIP Investment is set to ₹500. Minimum Lumpsum Investment is ₹5,000. Exit load of 0.50%, if redeemed within 3 months.
;
Investment Objective
The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare.
Fund benchmarkNIFTY Healthcare Total Return Index.
Fund house
Rank (total assets)--
Total AUM₹12,249.87 Cr
Date of Incorporation14 May 2018
Launch Date14 May 2018
AddressITI Asset Mangement Limited,ITI House, Building no. 36,Dr. R. K. Shirodkar Marg, Parel, Mumbai 400012
Websitewww.karvymfs.com
AddressKarvy House, No. 46, 8-2-609/K, Avenue 4, Street No.1 Banjara Hills,